MEDICAL INQUIRIES MEDICAL INQUIRIES

THERAPEUTIC AREAS THERAPEUTIC AREAS

DISEASE AWARENESS DISEASE AWARENESS

DRUG PORTFOLIO DRUG PORTFOLIO

CONGRESSES AND PUBLICATIONS CONGRESSES AND PUBLICATIONS

Contact Us

Call 1-888-275-7376
(8-5:30 ET M-F)

Submit Med Info Request

Adverse Event:
1-800-283-8088, ext. 5563

eMedI Chat: Medical Information Database

Please click the eMedI Chat icon in the lower right corner of your screen to use our chatbot and search the Medical Information database

Temperature Stability Calculator

Have a question about a temperature excursion?

Find Your Medical Representative

Find your Medical Representative based on your therapeutic area and zip code.

Therapeutic Areas

Discover our resource library on diseases, products, congresses, publications, and more, organized by therapeutic areas

Disease Awareness

Find information on disease areas of interest

Marketed Products

Find information on our marketed products

Pipeline Agents

Find information on our pipeline agents

Congress Presentations

Explore our library of congress presentations

Journal Publications

Discover our library of select journal publications

eMedI Chat

CMSC 2025

The Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2025 – May 28-31, 2024 / Phoenix, AZ

Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

Cladribine Tablets

Comparative Assessment of Treatment Switching for Cladribine Tablets Versus Fingolimod, Dimethyl Fumarate, and Teriflunomide in Patients with Multiple Sclerosis at 4 Years

Gupta A, et al.

Real-World Effectiveness and Safety of Cladribine Tablets in Patients with Relapsing Multiple Sclerosis After Suboptimal Response to Prior Injectable Therapy

Katz J, et al.

Post-Approval Safety of Cladribine Tablets in the Treatment of Patients With Multiple Sclerosis: 2024 Update

Leist T, et al.

Two-Year Findings on the Safety and Efficacy of Cladribine Tablets after Treatment with Natalizumab (CLADRINA Trial)

Sguigna P, et al.

Immune Cell and Inflammatory Marker Dynamics in Cerebrospinal Fluid After Treatment of Multiple Sclerosis With Cladribine Tablets: Results From the CLOCK-MS Study

Wu G, et al.

General Neurology

The MS-LINK™ Outcomes Study: Study Design and Descriptive Analyses of Patient-Reported Outcomes, Disease, and Sociodemographic Characteristics

English J, et al.

Quantitative Survey of Burnout Among Neurology Advanced Practice Providers (Physician Assistants and Nurse Practitioners) and Clinical Pharmacists in the United States

Walker B, et al.

This site is intended for US healthcare professionals only.

DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.

US-MULNP-00023 04/25

By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.

Welcome to EMD Serono Medical Information!

Help us direct you to the right information by selecting one of the following options: